Metallo-beta-lactamase-producing Pseudomonas aeruginosa isolated from a large tertiary centre in Kenya.

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
Johann D D PitoutLaurent Poirel

Abstract

This study was designed to characterize the beta-lactamase content of carbapenem-resistant Pseudomonas aeruginosa isolates recovered during 2006 and 2007 in a large tertiary-care centre in Nairobi, Kenya. Molecular characterization was done using PCR and sequencing, and typing was performed using pulsed-field gel electrophoresis (PFGE). In total, 416 P. aeruginosa isolates were obtained during that period, of which 57 (13.7%) were resistant to carbapenems. All carbapenem-resistant isolates tested positive for metallo-beta-lactamase (MBL) production. All MBL isolates produced VIM-2 with two types of integron structures. PFGE identified three clonally related groups of VIM-2-producing P. aeruginosa, including a pan-resistant clone that was responsible for nosocomial outbreaks during 2006 and 2007 in the intensive-care unit. These findings suggest that continuous molecular surveillance needs to be performed to monitor the spread within the hospital of this pan-resistant strain. This study is the first report of VIM-2-producing P. aeruginosa from the African continent.

References

Jun 27, 2002·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·P Nordmann, L Poirel
Oct 6, 2005·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Cécile AubronPatrice Nordmann
Aug 9, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David L Paterson
May 25, 2007·Diagnostic Microbiology and Infectious Disease·Yu-Tsung HuangJann-Tay Wang
Jul 27, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·C PeñaJ Ariza
Oct 12, 2007·Future Microbiology·Laurent PoirelPatrice Nordmann
Oct 24, 2007·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Osman Birol OzgumusIftihar Koksal
Jan 31, 2008·Expert Opinion on Investigational Drugs·Varsha Gupta

❮ Previous
Next ❯

Citations

May 3, 2011·The Lancet Infectious Diseases·Giuseppe CornagliaGian Maria Rossolini
Dec 31, 2010·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Sonia KtariAdnane Hammami
Mar 30, 2012·The Journal of Antimicrobial Chemotherapy·Rachael Kiera JacobsonColleen Bamford
Jul 28, 2013·The Journal of Antimicrobial Chemotherapy·Katy JeannotPatrick Plésiat
Nov 18, 2009·Antimicrobial Agents and Chemotherapy·Jose-Manuel Rodriguez-MartinezLaurent Poirel
Sep 10, 2009·Antimicrobial Agents and Chemotherapy·José-Manuel Rodríguez-MartínezPatrice Nordmann
Dec 2, 2010·Microbiology and Molecular Biology Reviews : MMBR·Vanderlene L KungAlan R Hauser
Apr 1, 2011·Future Microbiology·Wei-Hua Zhao, Zhi-Qing Hu
Dec 11, 2013·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Imane SefraouiJean-Marc Rolain
Jul 28, 2009·Diagnostic Microbiology and Infectious Disease·Wejdene MansourPatrice Nordmann
Mar 29, 2011·Critical Reviews in Microbiology·Chedly ChouchaniAllaaeddin El Salabi
Apr 11, 2015·International Journal of Antimicrobial Agents·Anaïs PotronPatrice Nordmann
Sep 28, 2014·The Journal of Antimicrobial Chemotherapy·Rendani I ManenzheMamadou Kaba
Dec 22, 2017·Medical Sciences : Open Access Journal·Francis S Codjoe, Eric S Donkor
Jan 4, 2018·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Jun Sung HongKyungwon Lee
Jul 15, 2015·Infection & chemotherapy·Duck Jin HongKyungwon Lee
Nov 12, 2019·Acta Microbiologica Et Immunologica Hungarica·Younes KhaliliMohammad Yousef Memar
Sep 2, 2018·BMC Research Notes·Kenneth SsekatawaFrancis Ejobi
Mar 9, 2021·Frontiers in Microbiology·Eun-Jeong Yoon, Seok Hoon Jeong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.